A PROVEN SAFETY PROFILE

The most common adverse reactions in clinical trials*:

  • 1.8% Headache
  • 1.8% Dizziness
  • 0.9% Rash
  • 0.9% Eczema
  • 0.9% Hypersensitivity reaction
    (nausea and tachycardia)

*In five multicenter, prospective, open-label clinical trials with IDELVION, 114 previously treated patients (PTPs; exposed to a Factor IX-containing product for ≥100 exposure days) received at least one infusion of IDELVION as part of on-demand treatment of bleeding episodes, perioperative management of major and minor surgical, dental, or other invasive procedures, routine prophylaxis, or pharmacokinetic evaluation. Twenty-seven children were <12 years of age, 9 adolescents were 12 to <18 years of age, and 78 adults were ≥18 to ≤65 years of age. A total of 16,326 injections were administered over a median of 1,543.5 days (range: 25 to 2,565 days).

7- And 14-day dosing

Two dosing schedules that meet your patient's individual needs

VIEW FULL DOSING INFORMATION
0 spontaneous bleeds

Patients who started and stayed on prophylaxis prove IDELVION has powerful efficacy with both 7- and 14-day dosing

VIEW EFFICACY DATA

†Once well-controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ?40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.

‡Of the 23 subjects in Arm 2, 19 were transitioned from on-demand to 7-day prophylaxis. The median AsBR during prophylaxis treatment was 0.7 (range: 0 to 4.2). Data for Arms 1 and 2 based on matched-pairs design.

X
You are now leaving the current website.

Do you want to continue?